You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Indolent B-cell non-Hodgkin's lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

    Active, not recruiting
    Has Results
    • Follicular Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 6, 2022

    Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

    Active, not recruiting
    • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
    • Nagoya, Aichi, Japan
    • +5 more
    Dec 10, 2021

    Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

    Recruiting
    • Indolent B-Cell Non-Hodgkin Lymphoma
    • BI1206
    • Atlanta, Georgia
    • +8 more
    Mar 1, 2022

    Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +11 more
    • Biopsy
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 3, 2023

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

    Completed
    Has Results
    • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Sep 20, 2022

    Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

    Recruiting
    • Aggressive B-Cell Non-Hodgkin Lymphoma
    • +19 more
    • CD47 Antagonist ALX148
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

    Active, not recruiting
    • Indolent B-cell Non-Hodgkin's Lymphoma
    • Anjo, Aichi, Japan
    • +29 more
    Dec 10, 2021

    CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

    Recruiting
    • CLL/SLL
    • +6 more
    • Duarte, California
    • +4 more
    Jan 12, 2023

    Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    • +8 more
    • Biospecimen Collection
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 8, 2023

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +2 more
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 5, 2023

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

    Recruiting
    • R/R CD19-Positive B-Cell Malignancies
    • +2 more
    • CNTY-101
    • +2 more
    • Detroit, Michigan
    • +1 more
    Dec 21, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +9 more
    • Cryosurgery
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 9, 2022

    Lymphoma, Non-Hodgkin Trial in Worldwide (Fludarabine, Cyclophosphamide, JCAR017)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Santa Monica, California
    • +36 more
    Jan 25, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 13, 2023

    Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +8 more
    • Miami, Florida
    • +2 more
    Apr 21, 2022

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

    Active, not recruiting
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +9 more
    • BTK inhibitor PCI-32765
    • +5 more
    • Columbus, Ohio
      Ohio State University Medical Center
    Jun 27, 2022

    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

    Completed
    • Multiple Myeloma
    • +7 more
    • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Nov 2, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +15 more
    • Anti-CD19/CD20/CD22 CAR T-Cells
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 4, 2022